Findings

What do systematic reviews say?

1,139 questions · 1,173 findings · 89 reviews · Neuromuscular

Sort:Best matchNewestHighest certainty Download CSV

No studies found 302 · 25.7%GRADE not reported 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%

Intervention not reported

Duration of hospitalization (in weeks) · individuals with infant botulism

1 finding from 1 review

Medical treatment for botulism 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 122 participants
Moderate

Intervention not reported

Duration of mechanical ventilation (in weeks) · individuals with infant botulism

1 finding from 1 review

Medical treatment for botulism 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Low

Intervention not reported

Duration of tube or parenteral feeding (in weeks) · individuals with infant botulism

1 finding from 1 review

Medical treatment for botulism 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 122 participants
Moderate

Intervention not reported

Risk of adverse events (until time of hospital discharge) · individuals with infant botulism

The intervention showed no clear difference in risk of adverse events (until time of hospital discharge) (moderate certainty).

1 finding from 1 review

Medical treatment for botulism 2019 · Cochrane Headline outcomes only
RR 0.92 [0.72, 1.18]
1 study · 129 participants
Moderate

Acetyl‐L‐carnitine vs placebo

Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · people with diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 540 participants
Very low

Acetyl‐L‐carnitine vs methylcobalamin

Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs methylcobalamin

Symptom quality and severity Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) · the treatment of diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 232 participants
Low

Acetyl‐L‐carnitine vs methylcobalamin

Adverse events · the treatment of diabetic peripheral neuropathy

Acetyl‐L‐carnitine showed no clear difference in adverse events compared with methylcobalamin (low certainty).

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
RR 1.01 [0.68, 1.52]
1 study · 232 participants
Low

Acetyl‐L‐carnitine vs placebo

Functional impairment and disability Assessed by NIS or NDS at 6 months or more · people with diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs placebo

Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 341 participants
Very low

Acetyl‐L‐carnitine vs placebo

Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs placebo

Symptom quality and severity Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more · people with diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 participants
GRADE not reported

Acetyl‐L‐carnitine vs placebo

Adverse events: any adverse event, adverse events requiring withdrawal, and serious adverse events · people with diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 540 participants
Low

Acetyl‐L‐carnitine vs methylcobalamin

Pain at 6 months or more · the treatment of diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acetyl‐L‐carnitine vs methylcobalamin

Functional impairment and disability Assessed by change in NDS score (range of possible scores from 0 (normal function) to 10 (maximal disability) · the treatment of diabetic peripheral neuropathy

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 232 participants
Low

Acetyl‐L‐carnitine vs methylcobalamin

Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Respiratory muscle training vs sham training

Change in FVC · people with ALS

1 finding from 1 review

Respiratory muscle training in children and adults with neuromuscular disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Low

Respiratory muscle training vs sham training

Measures of lung capacity over the long term (greater than 1 year) · children and young males with DMD

The review found no eligible studies for this question.

1 finding from 1 review

Respiratory muscle training in children and adults with neuromuscular disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Respiratory muscle training vs sham training

Activities of daily living · children and young males with DMD

The review found no eligible studies for this question.

1 finding from 1 review

Respiratory muscle training in children and adults with neuromuscular disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Respiratory muscle training vs sham training

Quality of life · children and young males with DMD

The review found no eligible studies for this question.

1 finding from 1 review

Respiratory muscle training in children and adults with neuromuscular disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found